Protodigm collaborates with research institute on heart disease dataset

By Jenni Spinner contact

- Last updated on GMT

(ExperienceInteriors/iStock via Getty Images Plus)
(ExperienceInteriors/iStock via Getty Images Plus)

Related tags: Heart, cardiovascular disease, thrombosis, data analysis, Data management

The company is joining with the Thrombosis Research Institute on the creation of a heart disease patient dataset to advance precision medicine development.

Protodigm has announced its collaboration with the Thrombosis Research Institute (TRI) on the launch of a patient study, designed to enable the development of precision medicine solutions to fight cardiovascular disease.

TRI reportedly will lead the study and:

  • provide a global steering committee
  • host the database and biobank
  • use its clinical trial network consisting of more than 2,000 sites in 35 countries.
  • enable intensive dataset interrogation of the dataset via the development of 'digital twins', machine learning algorithms, and other advanced technologies.

Also, Protodigm is set to provide pharmaceutical liaison and asymmetric learning to the study datasets. The goal is to help generate unique insights and knowledge gaps, build plans to learn, and identify potential therapeutic development paths.

Cardiovascular diseases are the leading cause of death globally, according to the World Health Organization (WHO); they claim approximately 17.9m lives around the world each year. However, according to the collaborators, the application of next-generation data science techniques stands to help abate the pervasive, deadly problem.

"This project represents a unique opportunity to follow a diverse group of patients, derive novel insights, and meaningfully improve outcomes globally in cardiovascular disease​," said Vijay Kakkar, TRI president.

"Protodigm is deeply committed to applying leading-edge advances in data science and learning to accelerate insight-driven innovation​,” commented Protodigm CEO Mike Rea. “The collaboration with TRI provides a unique opportunity to demonstrate this concept—this project will shape the future of big data science for our industry.​"

Protodigm and TRI are inviting other biotechnology and pharmaceutical companies to join their pre-competitive alliance. The study reportedly is expected to run for four years.

Related news

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us


View more